111 related articles for article (PubMed ID: 25710585)
41. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
42. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Affolter K; Samowitz W; Tripp S; Bronner MP
Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
[TBL] [Abstract][Full Text] [Related]
43. Histologic and molecular analyses of colonic perineurial-like proliferations in serrated polyps: perineurial-like stromal proliferations are seen in sessile serrated adenomas.
Pai RK; Mojtahed A; Rouse RV; Soetikno RM; Kaltenbach T; Ma L; Arber DA; Plesec TP; Goldblum JR; Pai RK
Am J Surg Pathol; 2011 Sep; 35(9):1373-80. PubMed ID: 21836484
[TBL] [Abstract][Full Text] [Related]
44. Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases.
Kwon MJ; Min BH; Lee SM; Park HY; Kang SY; Ha SY; Lee JH; Kim JJ; Park CK; Kim KM
Histol Histopathol; 2013 Apr; 28(4):453-62. PubMed ID: 23404616
[TBL] [Abstract][Full Text] [Related]
45. Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma.
Moy AP; Arora K; Deshpande V
Histopathology; 2016 Sep; 69(3):423-30. PubMed ID: 26841202
[TBL] [Abstract][Full Text] [Related]
46. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
48. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
49. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
[TBL] [Abstract][Full Text] [Related]
50. Histologic Features Do Not Reliably Predict Mismatch Repair Protein Deficiency in Colorectal Carcinoma: The Results of a 5-Year Prospective Evaluation.
Olevian DC; Pai RK
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):231-238. PubMed ID: 29189259
[TBL] [Abstract][Full Text] [Related]
51. Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma.
Reagh J; Clarkson A; Bullock M; Shepherd P; Gill AJ
Pathology; 2018 Apr; 50(3):342-344. PubMed ID: 29477276
[No Abstract] [Full Text] [Related]
52. BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma.
Ng JY; Lu CT; Lam AK
Histol Histopathol; 2019 May; 34(5):469-477. PubMed ID: 30592501
[TBL] [Abstract][Full Text] [Related]
53. Comparative Study of DNA ploidy and BRAF Immunohistochemistry between Colonic Adenocarcinoma and Inflammatory Colonic Lesions.
Khalil HKM; Hammam OA; Anis SE; Elashry MAE; El-Yasergy DF
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1389-1400. PubMed ID: 37116163
[TBL] [Abstract][Full Text] [Related]
54. Screening for Lynch syndrome: a no-brainer: BRAF V600E mutation-specific immunohistochemistry: caveat emptor.
Bellizzi AM
Am J Clin Pathol; 2015 Mar; 143(3):320-4. PubMed ID: 25696788
[No Abstract] [Full Text] [Related]
55. Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values.
Marquet B; Marchal Bressenot A; Fichel C; Bouland N; Barbe C; Bouché O; Kianmanesh R; Diebold MD; Boulagnon-Rombi C
Pathol Oncol Res; 2020 Oct; 26(4):2509-2521. PubMed ID: 32583331
[TBL] [Abstract][Full Text] [Related]
56. Lymphoepithelioma-like carcinoma of the colon in a patient with hereditary nonpolyposis colorectal cancer.
De Petris G; Lev R; Quirk DM; Ferbend PR; Butmarc JR; Elenitoba-Johnson K
Arch Pathol Lab Med; 1999 Aug; 123(8):720-4. PubMed ID: 10420231
[TBL] [Abstract][Full Text] [Related]
57. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.
Joyce T; Oikonomou E; Kosmidou V; Makrodouli E; Bantounas I; Avlonitis S; Zografos G; Pintzas A
Curr Cancer Drug Targets; 2012 Sep; 12(7):873-98. PubMed ID: 22515520
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemistry versus next-generation sequencing for the routine detection of BRAF V600E mutation in melanomas.
Just PA; Audebourg A; Pasmant E; Clauser E; Carlotti A; Laurent S; Avril MF; Vacher-Lavenu MC; Vidaud M; Terris B
Hum Pathol; 2014 Sep; 45(9):1983-4. PubMed ID: 25074543
[No Abstract] [Full Text] [Related]
59. Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality?
Galissier T; Schneider C; Nasri S; Kanagaratnam L; Fichel C; Coquelet C; Diebold MD; Kianmanesh R; Bellon G; Dedieu S; Marchal Bressenot A; Boulagnon-Rombi C
PLoS One; 2016; 11(4):e0154326. PubMed ID: 27124490
[TBL] [Abstract][Full Text] [Related]
60. Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia.
Shah H; McPherson K; Mansour A; Ramirez-Santrich C; Nassiri M; Shahda S
Clin Colorectal Cancer; 2016 Dec; 15(4):e235-e239. PubMed ID: 27117521
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
